Research programme: siRNA therapeutics - Suzhou Ribo Life Sciences

Latest Information Update: 26 Jul 2016

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Suzhou Ribo Life Science
Class RNA
Mechanism of Action RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Research Fibrosis; HIV infections; Liver cancer; Pancreatic cancer

Most Recent Events

26 Jul 2016 Research programme: siRNA therapeutics - Suzhou Ribo Life Sciences is available for licensing - http://www.ribolia.com/en/development/index.aspx?BasicClassId=552&HeadID=5
26 Jul 2016 Early research in Fibrosis in China (Parenteral)
26 Jul 2016 Early research in HIV infections in China (Parenteral)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.